Amadeus and Sigfox Partner to Transform the Travel Industry’s Tracking Capabilities
26.11.2019 14:56:00 EET | Business Wire | Press release
Sigfox, the world’s leading Internet of Things (IoT) service provider and first global 0G network operator and Amadeus, the leading provider of IT solutions for the travel and tourism industry, announce a new strategic partnership at Sigfox Connect 2019. The agreement results from a year-long collaboration investigating business opportunities within the travel industry and developing a portfolio of solutions that will not only help meet the growing need for efficient asset tracking solutions, but also reduce operational challenges for airports and airlines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005416/en/
PinPoint, an Amadeus and Sigfox strategic alliance (Photo: Sigfox)
The unique combination of Sigfox IoT expertise and Amadeus’ in-depth travel industry knowledge sees the emergence of disruptive services that will hit the market in 2020 thanks to the Sigfox and Amadeus strategic alliance, called PinPoint.
PinPoint aims at providing best-in-class end-to-end tracking solution for the air transportation industry. It targets indeed initially airports and airlines with trackers optimally designed - connected and communicating through the Sigfox 0G global network and managed through the PinPoint platform.
Every year, airports and airlines handle billions of pieces of luggage and high-value assets which are often lost, damaged or delayed leading to high financial losses for the whole value chain, a lack of operational efficiency, and increasing dissatisfaction for travelers. Meanwhile, existing tracking technologies require expensive infrastructure updates, such as gates and readers and provide limited interoperability and geolocation capabilities. In parallel, regulation is increasingly demanding, especially the new IATA Resolution 753 on luggage tracking which imposes stricter tracking and increased visibility requirements to reduce luggage loss rates.
With this in mind, PinPoint aims to provide a new journey for travel industry assets through reusable, cost and energy-efficient, and globally connected trackers that offer airports and airlines access to real-time information about the location of luggage and high value assets, such as spare-parts, landing gear, Unit Load Devices (ULD) and much more.
Through reusable tags placed on luggage, proximity sensors installed across airports and Sigfox global coverage, airlines will be able to monitor luggage, accurately tracking its location and detecting anomalies. For high-value assets such as ULDs, airlines will be able to use this technology to collect data, enabling ULDs to report any movement, so optimizing ULD management and significantly reducing the risk of loss.
Sigfox Bubble technology, an innovative beaconing solution enabling proximity detection, will also be developed and deployed in collaboration with Sigfox new partner Alps Alpine, one of the world’s foremost manufacturers of electronics components. By managing the emission power, Sigfox Cloud adapts the range of the Bubble, from less than one meter to a few tens of meters, improving the accuracy of the device’s location. Thus, when entering a Bubble cell, Sigfox devices and associated assets share their identification to the cloud providing a highly accurate location for each asset.
“We are delighted to strengthen our partnership with Amadeus and share our combined expertise to create real digital transformation of the travel sector. Our strategic alliance named PinPoint will not only help to improve the travel experience, but this will also change completely the game for an industry looking for decades for THE technology able to save costs while improving efficiency and quality of services”, explains Raouti Chehih, Chief Adoption Officer at Sigfox.
“Sigfox technology is unique in its ability to track objects seamlessly across the globe, and at such a low cost. Combining Amadeus expertise and partners’ network in travel with Sigfox technology, we can enable luggage tracking at a price which is within what consumers are ready to pay for, and thus bring peace of mind to billions of travelers.” Marion Mesnage, Head of Research, Innovation & Ecosystems, Amadeus.
This new solution leverages Sigfox IoT expertise and unique 0G network while harnessing Amadeus trusted relationships within the travel industry to reduce costs for airlines and airports, deliver higher operational efficiency, generate ancillary revenues, and increase customer satisfaction.
This alliance, which aims in time to become a joint venture, is the starting point of a new journey that could revolutionize the travel industry. Although airports and airlines are the main targets today, in the future, Sigfox and Amadeus aspire to reach out to new sectors like hospitality to offer end-to-end tracking solutions that will cover the full traveler journey.
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 65 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
About Amadeus
Travel powers progress. Amadeus powers travel. Amadeus’ solutions connect travelers to the journeys they want through travel agents, search engines, tour operators, airlines, airports, hotels, cars and railways.
We have developed our technology in partnership with the travel industry for over 30 years. We combine a deep understanding of how people travel with the ability to design and deliver the most complex, trusted, critical systems our customers need. We help connect over 1.6 billion people a year to local travel providers in over 190 countries.
We are one company, with 19,000 employees across 70 offices. We have a global mindset and a local presence wherever our customers need us.
Our purpose is to shape the future of travel. We are passionate in our pursuit of better technology that makes better journeys.
Amadeus is an IBEX 35 company, listed on the Spanish Stock Exchange under AMS.MC. The company is also part of the EuroStoxx50 and has been recognized by the Dow Jones Sustainability Index for the last eight years.
To find out more about Amadeus, visit www.amadeus.com.
Follow us on: Facebook / Twitter / LinkedIn / YouTube / Site web Amadeus
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005416/en/
Contact information
Media
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com
Archetype for Sigfox
Rémi Fresnel
remi.fresnel@archetype.co
+33 (0)6 78 26 96 75
Amadeus
Bertrand Cognard, Corporate Communications
Bertrand.cognard@amadeus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
